Medicare Part D Conference To Address MMA Implications For Pharmaceutical Field Sales June 27-28, 2005 In Washington, D.C.

WASHINGTON, March 18 /PRNewswire/ -- Medicare Part D under the Medicare Modernization Act (MMA) promises to have a significant effect on pharmaceutical sales forces. As Medicare formularies gain significant mindshare in their respective regions, “spill-over” effects could significantly impact physicians’ prescribing behaviors for Medicare as well as privately covered patients. This may require sales forces to alter their approaches to targeting, territory alignment, incentive compensation, and pull-through. Join us at the “Medicare Part D: Ramifications for the Pharmaceutical Industry at the Corporate and Product Levels” conference organized by Strategic Research Institute in association with Campbell Alliance. The conference is scheduled to take place June 27-28, 2005 at the Westin Grand Hotel in Washington D.C.

The two day intensive information and networking event features senior- level executives from major pharmaceutical and biotech companies, managed care organizations, pharmacy benefit managers, and other related healthcare organizations. The conference agenda will feature a variety of case study presentations, panel discussions and keynotes. Some of the topics covered include:

- Impact of Part D Regions on Pharmaceutical Companies’ Commercial Managed Care Business - The Impact of Medicare Part D on State Medicaid Programs - The Evolving Role of Health Economics and Outcomes Research Under Part D - Impact of the MMA on Interactions Between Account Managers and Managed Care Customers - Compliance and Persistence in the Medicare Population - Potential Impact of ePrescribing - Key Strategies for Communicating with the Senior Market - Market Research Needs in a New Competitive Landscape - The Shifting Role of PBMs - Segmentation of the Senior Market and Implications for Pharmaceutical Companies - Physician Prescribing Habits - The Future of Medicare: Possible Changes on the Horizon and How Pharmaceutical Companies Can Prepare

For more information, please contact Mark Alexay at malexay@srinstitute.com or call 212.967.0095, ext. 251 or Glenn Pascual at gpascual@srinstitute.com or call 212.967.0095, ext. 245

Strategic Research Institute

CONTACT: Mark Alexay, +1-212-967-0095, ext. 251,malexay@srinstitute.com, or Glenn Pascual, +1-212-967-0095, ext. 245,gpascual@srinstitute.com, both of Strategic Research Institute